posted Feb 3, 2019, 3:34 AM by Scott Salisbury
[
updated Feb 3, 2019, 6:47 AM
]
US6630507B1 UNITED STATES OF AMERICA AbstractCannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.
Texas  NBC 5 Dallas-Fort Worth Dallas pharmacist Emile Abdo, who sells CBD products, said he supports so-called "truth-in-labeling" laws, because "there's a lot of products out there that are mislabeled."
Vermont
The Government of The United States.
Additionally, it’s unlawful under the FD&C Act to introduce food containing added CBD or THC into interstate commerce, or to market CBD or THC products as, or in, dietary supplements, regardless of whether the substances are hemp-derived. This is because both CBD and THC are active ingredients in FDA-approved drugs and were the subject of substantial clinical investigations before they were marketed as foods or dietary supplements. Under the FD&C Act, it’s illegal to introduce drug ingredients like these into the food supply, or to market them as dietary supplements. This is a requirement that we apply across the board to food products that contain substances that are active ingredients in any drug.
FDA Responds to Three GRAS Notices for Hemp Seed-Derived Ingredients for Use in Human Food
These GRAS conclusions do not affect the FDA’s position on the addition of CBD and THC to food. As stated on FDA and Marijuana: Questions and Answers, it is a prohibited act under section 301(ll) of the Federal Food, Drug, and Cosmetic Act to introduce into interstate commerce a food to which CBD or THC has been added.
FDA Approves First Drug Derived from Marijuana Epidiolex® is the first FDA-approved medication made from a purified extract of the marijuana plant
Approved in the USA. GW Pharmaceuticals anti-seizure properties. Drug name... Epidiolex®
Approved in the UK. GW Pharmaceuticals consists of equal parts THC and CBD and is approved in the UK to treat spasticity, neuropathic pain, and other symptoms of multiple sclerosis; it has not been approved in the US... Drug name... Sativex®
Disentangling the impairing effects of THC from its potentially therapeutic properties (for instance in treating pain and nausea) has been a challenge in developing safe medications that target the body’s endocannabinoid system.
|
|